[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637431":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":37,"locations":42,"responsibleParty":44,"collaborators":46,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":42,"enrollmentInfo":63,"targetDuration":42,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":78,"whyStopped":42,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":42},{"fullName":5,"class":6},"Prostate Cancer Clinical Trials Consortium","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Mevrometostat + Enzalutamide","EXPERIMENTAL","Mevrometostat 875 mg orally twice daily (BID) with food in combination with enzalutamide 160 mg orally once daily. Treatment continues until confirmed radiographic disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria.",[13,14],"Drug: Mevrometostat","Drug: Enzalutamide",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Mevrometostat","875 mg oral tablet, taken twice daily with food",[9],[22],"PF-06821497",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Enzalutamide","160 mg oral capsule, taken once daily",[9],[28],"Xtandi",[30,34],{"name":31,"affiliation":32,"role":33},"Michael Schweizer, MD","University of Washington- Fred Hutch Cancer Center","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":36,"role":33},"Atish Choudhury, MD, PhD","Dana-Farber Cancer Institute",[38],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Sarah Wise","CONTACT","215-380-9051",null,"wises@mskcc.org",{"type":45,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR",[47,50,51],{"name":48,"class":49},"Pfizer","INDUSTRY",{"name":36,"class":6},{"name":52,"class":6},"Fred Hutchinson Cancer Center","100637431","phase-2-a-study-of-mevrometostat-with-enzalutamide-in-people-with-prostate-cancer-who-have-previously-received-androgen-receptor-pathway-inhibitor-therapy-100637431",false,"NCT07592910","A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy","A Phase 2, Open-label, Single-Arm Study of Mevrometostat Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Following Prior Androgen Receptor Pathway Inhibitor Therapy (MOMENT)","MOMENT","Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* Age 18 years or older\n* Diagnosis of prostate cancer (adenocarcinoma) confirmed by tissue sample, without neuroendocrine or small cell features\n* Currently taking or recently treated with enzalutamide, darolutamide, or apalutamide (within 30 days of screening) and willing to switch to or restart enzalutamide for this study\n* Cancer has spread to bone or soft tissue (metastatic disease), confirmed by imaging\n* ECOG performance status of 0, 1, or 2 (able to care for self and up and about more than 50% of waking hours)\n* Testosterone level less than 50 ng\u002FdL at screening, with ongoing hormone deprivation therapy or prior surgical castration\n* If receiving bone-protective therapy (e.g., denosumab or bisphosphonates), must be on a stable dose for at least 4 weeks\n* Evidence of cancer progression while on enzalutamide, darolutamide, or apalutamide, shown by rising PSA, worsening disease on imaging, or new bone lesions\n* Adequate organ function based on blood tests within 28 days of starting treatment, including adequate blood counts, kidney function, and liver function\n* Willing to use acceptable birth control during the study and for 30 days after the last dose\n\nExclusion Criteria:\n\n* History of myelodysplastic syndrome, acute myeloid leukemia, or other prior cancer (exceptions: non-melanoma skin cancer, carcinoma in situ, cancers more than 3 years ago with no recurrence, or early-stage cancers with low risk of recurrence)\n* Any medical or psychiatric condition, including active infection or recent suicidal ideation, that may make study participation unsafe\n* History of seizure or conditions that may increase seizure risk (e.g., prior stroke, significant brain trauma), or loss of consciousness or transient ischemic attack within 12 months\n* Untreated brain metastases, spinal cord compression, or clinically significant epidural disease\n* Use of 5-alpha reductase inhibitors, herbal medications, or supplements known to alter PSA levels within 4 weeks of starting treatment\n* AIDS-related illness or active hepatitis B or C (well-controlled HIV is allowed)\n* Known history of chronic liver disease (e.g., alcoholic liver disease, primary biliary cirrhosis, autoimmune hepatitis, Wilson's disease, hemochromatosis)\n* Known history of active inflammatory gastrointestinal disease, chronic diarrhea, or prior gastric resection or lap-band surgery\n* Clinically significant cardiovascular disease within the past 6 months (e.g., heart attack, unstable angina, stroke, heart failure NYHA Class III\u002FIV, pulmonary embolism, significant arrhythmias), cardiac pacemaker, or QTcF greater than 480 msec on screening ECG\n* Prior or current use of PARP inhibitors and\u002For AKT inhibitors\n* Prior cancer progression on abiraterone (stopping abiraterone due to side effects is allowed)\n* Known allergy to any study drug\n* Blood transfusion within 28 days prior to screening blood tests\n* Use of another investigational drug within 4 weeks before starting study treatment\n* Any other condition that, in the opinion of the investigator, would prevent safe participation\n* Current use or anticipated need for strong CYP3A4\u002F5 inhibitors or inducers (other than enzalutamide) within 10 days or 5 half-lives prior to treatment start","MALE","18 Years",{"count":64,"type":65},60,"ESTIMATED","INTERVENTIONAL",[68],"PHASE2","The purpose of this study is to find out whether mevrometostat in combination with enzalutamide delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have previously received enzalutamide, darolutamide, or apalutamide in the metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC) setting but have not previously progressed on abiraterone.",[71,72],"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","Prostate Cancer (Adenocarcinoma)",[18,74,24,75,59,76,77],"EZH2 inhibitor","ARPI resistance","mCRPC","Prostate Cancer","NOT_YET_RECRUITING","2026-05-11",{"date":81,"type":82},"2026-05-18","ACTUAL",{"date":84,"type":65},"2026-08",{"date":86,"type":65},"2029-08",{"name":5,"class":6}]